financetom
Business
financetom
/
Business
/
Japan's Sojitz buys US sushi business in seafood expansion drive
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Japan's Sojitz buys US sushi business in seafood expansion drive
Jul 30, 2024 3:49 AM

TOKYO (Reuters) - Japanese trading house Sojitz ( SZHFF ) said on Tuesday it had bought the takeout sushi businesses of Sushi Avenue Inc in the United States for an undisclosed sum, as part of a drive to expand its seafood operations.

Sojitz ( SZHFF ) is aiming to boost annual net profit from seafood operations to 4 billion yen ($26 million) in the year to March 2027 from 1.2 billion yen in the year ended March 2024.

"We are taking on the challenge of becoming the world's No.1 distinctive marine products group, with strength in tuna and sushi products," finance chief Makoto Shibuya told reporters.

"We aim to boost the profitability of domestic seafood operations and strengthen initiatives in growing overseas markets," he said.

The U.S. sushi market has grown to almost 1.6 times the size of the market in Japan, according to Sojitz ( SZHFF ), with favourites such as California rolls becoming a staple of American cuisine and nigiri sushi growing in popularity.

Shibuya said the purchase price was several billions of yen, without giving an exact figure.

Sushi Avenue operates a supermarket takeout sushi business with over 300 retail locations in the Midwest and across the United States.

In entering the United States, Sojitz ( SZHFF ) aims to leverage the procurement and product development expertise of its Japanese seafood business.

Japanese trading houses have been investing in the seafood sector, with Mitsubishi Corp ( MSBHF ) owning a Norwegian salmon producer and Mitsui & Co ( MITSF ) buying into an Ecuadoran shrimp farming company.

Asked whether Sojitz ( SZHFF ) would also invest in salmon farming, Shibuya said it might if there was a good opportunity.

Sojitz ( SZHFF ) reported a 4.1% rise in net profit for the April-June quarter to 23.04 billion yen and stuck to its full-year profit forecast of 110 billion yen.

The company plans to withdraw from its Philippines car business by the end of this year due to a slumping performance amid fierce competition.

($1 = 154.7400 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Humana loses bid to challenge downgrade to US Medicare 'star' ratings
Humana loses bid to challenge downgrade to US Medicare 'star' ratings
Jul 18, 2025
* Judge dismisses Humana's lawsuit for not exhausting out-of-court options * CMS star ratings affect government reimbursement, bonuses for Medicare plans * Humana's lawsuit challenged CMS star ratings for 2025 By Diana Novak Jones July 18 (Reuters) - A federal judge in Texas on Friday tossed a lawsuit brought by Humana that challenged the U.S. government's reduction in the health...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Market Chatter: FDA to Ask Sarepta Therapeutics to Halt Shipments of Gene Therapy Elevidys
Market Chatter: FDA to Ask Sarepta Therapeutics to Halt Shipments of Gene Therapy Elevidys
Jul 18, 2025
01:40 PM EDT, 07/18/2025 (MT Newswires) -- The US Food and Drug Administration will ask Sarepta Therapeutics ( SRPT ) to voluntarily halt all shipments of Elevidys, its gene therapy for the treatment of Duchenne muscular dystrophy, Reuters reported Friday, citing a source familiar with the matter. Sarepta didn't immediately reply to a request for comment from MT Newswires. Shares...
Elevance Health Insider Bought Shares Worth $2,438,951, According to a Recent SEC Filing
Elevance Health Insider Bought Shares Worth $2,438,951, According to a Recent SEC Filing
Jul 18, 2025
01:46 PM EDT, 07/18/2025 (MT Newswires) -- Gail Boudreaux, Director, President and CEO, on July 18, 2025, executed a purchase for 8,500 shares in Elevance Health ( ELV ) for $2,438,951. Following the Form 4 filing with the SEC, Boudreaux has control over a total of 151,080 common shares of the company, with 151,020 shares held directly and 60 controlled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved